Income Statement
TSCAN THERAPEUTICS, INC.
TCRX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
10.33 | 2.82 | 21.05 | 13.54 | 10.14 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
10.33 | 2.82 | 21.05 | 13.54 | 10.14 |
|
Operating Expenses
|
146.14 | 137.64 | 114.51 | 80.17 | 58.78 |
|
Research & Development
|
114.15 | 107.35 | 88.15 | 59.82 | 44.95 |
|
Selling, General & Administrative
|
31.99 | 30.29 | 26.35 | 20.35 | 13.83 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-135.81 | -134.82 | -93.46 | -66.64 | -48.64 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
2.77 | 3.65 | 3.76 | 1.18 | - |
|
Other Non-Op Income / Expense
|
6.05 | 7.32 | 4.24 | 0.42 | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-129.77 | -127.50 | -89.22 | -66.22 | -48.63 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-135.81 | -134.82 | -93.46 | -66.64 | -48.64 |
|
Earnings Per Share (Basic)
|
-1.00 | -1.14 | -1.36 | -2.75 | - |
|
Diluted EPS
|
-1.00 | -1.14 | -1.36 | -2.75 | - |
|
Weighted Average Shares
|
129.78 | 111.99 | 65.60 | 24.05 | - |
|
Diluted Weighted Avg Shares
|
129.78 | 111.99 | 65.60 | 24.05 | - |
|
Comprehensive Income
|
-129.82 | -127.45 | - | - | - |